Zynerba Press Releases

12 Mar 18 Zynerba Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Operational Highlights

5 Mar 18 Zynerba Pharmaceuticals Announces Positive Meeting with U.S. Food and Drug Administration and Plans to Conduct a Single Pivotal Study of ZYN002 in Fragile X Syndrome to Support an NDA Filing

3 Jan 18 Zynerba Pharmaceuticals Provides 2018 Clinical and Corporate Update

3 Dec 17 Zynerba Pharmaceuticals Announces New ZYN002 Data from STAR 1 and STAR 2 Studies in Patients with Focal Seizures at the 2017 Annual Meeting of the American Epilepsy Society (AES)

21 Nov 17 Zynerba Pharmaceuticals Announces Poster Presentation at the 2017 Annual Meeting of the American Epilepsy Society (AES)

14 Nov 17 Zynerba Pharmaceuticals Reports Third Quarter 2017 Financial Results and Operational Highlights

7 Nov 17 Zynerba Pharmaceuticals to Present at Upcoming Investor Conferences

28 Sep 17 Zynerba Pharmaceuticals Announces Positive Top Line Results in ZYN002 Open Label Phase 2 FAB-C Study in Children with Fragile X Syndrome

6 Sep 17 Zynerba Pharmaceuticals to Participate in Upcoming Investor Conferences

14 Aug 17 Zynerba Pharmaceuticals Announces that Results from Phase 2 STOP Trial Support Continued Development of ZYN002 in Osteoarthritis